 |
| Introducing Velacur™ |
the first portable liver assessment tool with
S-WAVE technology. |
| S-WAVE* technology is a new generation of elastography that incorporates key elements of MRE and liver visualization to deliver deeper, larger 3D tissue sampling than conventional transient elastography. |
| *Shear Wave Absolute Vibro-Elastography (S-WAVE) |
 |
| Velacur™ provides real-time assessments of liver elasticity and attenuation. Low-cost and portable, Velacur is designed for easy, point-of-care use by trained assistants during in-office patient consultations. |
|
|
| Two NASH Drugs are on the Horizon for Market Approval: |
| Is Your Practice Ready? |
| Live Webinar |
| March 29, 2023 @ 2pm EST/11am PST |
|
|
| Join expert panel Stephen Harrison, Maru Rinella, and Mazen Noureddin as they discuss the practical implications of a NASH Drug Appoval. |
|
| What protocols will be required to prescribe and monitor these new drugs? |
| How will workflows need to adjust? |
| What role will primary care and other referring physicians play? |
| What are the reimbursement considerations? |
| What dose this mean in the context of the recently published guidance from AASLD on the management of NAFLD? |
|
|
|
|
 |
Learn how to integrate Velacur in your practice as a tool
for managing chronic liver disease. |
| For more information or to request a demo, |
| visit Velacur.com or call 1-800-881-0096. |
|
|
